



ABN 30 116 800 269

Level 7, 1008 Hay Street
Perth WA 6000
PO Box 7209
Cloisters Square WA 6850

Ph +61 8 9389 2000
Fax +61 8 9389 2099
info@erinresources.com

22 June 2015

ASX Release

MGC's Australian Roadshow and Website Launch

Erin Resources (ASX:ERI or the Company) is pleased to advise Mr Nativ Segev, MGC Pharmaceutical's Co-Founder and Managing Director and Mr Roby Zomer, Co-Founder and Director of Business Development have arrived in Australia to roadshow the company's business strategy in the rapidly expanding global medical cannabis market, in Sydney, Melbourne and Perth.

This roadshow is being undertaken following the signing of its initial €40,000,000 offtake supply agreement with Natura Laboratories and the recent approval of licenses for MGC to grow, extract resin and sell Cannabis Savita from its initial operations in Slovenia, directly into the European Union.

The Company also advises that as of today the newly designed corporate website for MGC Pharmaceuticals Limited (MGC) is live and can be located by current and potential investors at the following URL: www.mgcpharma.com.au

As a newly formed business it was important for MGC to make information related to its business operations, products and the industry available to the market and provide potential investors and clients with the knowledge to understand the business better. MGC will use the website to make available company and industry news and to provide expert insights into the market.

The commercial website will later be launched, which will entail further upgrades to include the functionality to browse and purchase from the business's product range.

-Ends-

For further information please contact:

Media Enquiries

Asher Moses
Director
Media and Capital Partners
+61 438 008 616
Asher.moses@mcpartners.com.au

Erin Resources Limited

Brett Mitchell
Executive Director
+61 8 9389 2000
info@erinresources.com.au

About MGC Pharmaceuticals

MGC Pharmaceuticals Limited (MGC) is an EU based medical and cosmetic cannabis company with over 40 years of technical and commercial experience in the medical and cosmetics cannabis industry. The Company's core focus and strategy is to develop and supply high quality non-psychoactive Cannabinoid resin extract ("CBD") to the growing European cosmetics market, through its industry experienced Israeli executive team.

About Erin Resources Option to Acquire MGC Pharmaceuticals

Erin Resources has entered into a binding heads of agreement with the option to acquire 100% of the issued capital of MGC Pharmaceuticals, as announced on 18 May 2015. The Option may be exercised within six months by Erin Resources from the date of HOA execution. The exercise of the Option will trigger the formal acquisition process and a full re-compliance with the ASX listing rules.